Analysis of CD8 T-cell response by IFNγ ELISPOT and H-2Ld/pRL1a tetramer assays in pRL1a multiple antigen peptide-immunized and RL male 1-bearing BALB/c and (BALB/c × C57BL/6)F1 mice

Cancer Science

Volumn 95, Issue 3, 2004, Pages 254-259

  Takada, Itsuro ^a   Noguchi, Yugi ^a   Kenjo, Akira ^b   Wada, Hisashi ^c   Uenaka, Akiko ^a   Fujita, Teizo ^b   Inoue, Hajime ^a   Nakayama, Eiichi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD8 ANTIGEN; GAMMA INTERFERON; PADGEM PROTEIN; TETRAMER; TUMOR ANTIGEN;

ALLOGRAFT; ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNIZATION; CANCER TRANSPLANTATION; CELL COUNT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG DETERMINATION; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; FEMALE; FREQUENCY ANALYSIS; IMMUNE RESPONSE; IMMUNOSTIMULATION; IN VITRO STUDY; INOCULATION; LEUKEMIA; MOLECULAR RECOGNITION; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; STRAIN DIFFERENCE; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TIME;

ANIMALS; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; H-2 ANTIGENS; HUMANS; IMMUNIZATION; INTERFERON-ALPHA; L-SELECTIN; LEUKEMIA, EXPERIMENTAL; LEUKEMIA, RADIATION-INDUCED; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; OLIGOPEPTIDES; PEPTIDES; POLYMERASE CHAIN REACTION;

EID: 1842867000     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2004.tb02212.x     Document Type: Article

References (22)

1. Nakayama E, Shiku H, Takahashi H, Oettgen HF, Old LJ. Definition of a unique cell surface antigen of mouse leukemia RL male 1 by cell-mediated cytotoxicity. Proc Natl Acad Sci USA 1979; 76: 3486-90.
2. Uenaka A, Ono T, Akisawa T, Wada H, Yasuda T, Nakayama E. Identification of a unique antigen peptide pRL1 on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the akt oncogene. J Exp Med 1994; 180: 1599-607.
3. Manki A, Ono T, Uenaka A, Seino Y, Nakayama E. Vaccination with multiple antigen peptide as rejection antigen peptide in murine leukemia. Cancer Res 1998; 58: 1960-4.
4. Ota S, Ono T, Morita A, Uenaka A, Harada M, Nakayama E. Cellular processing of a multibranched lysine core with tumor antigen peptides and presentation of peptide epitopes recognized by cytotoxic T lymphocytes on antigen-presenting cells. Cancer Res 2002; 62: 1471-6.
5. Murali-Krishna K, Altman JD, Suresh M, Sourdive DJ, Zajac AJ, Miller JD, Slansky J, Ahmed R. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 1998; 8: 177-87.
6. Tan LC, Gudgeon N, Annels NE, Hansasuta P, O'Callaghan CA, Rowland-Jones S, McMichael AJ, Rickinson AB, Callan MF. A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol 1999; 162: 1827-35.
7. Anichini A, Molla A, Mortarini R, Tragni G, Bersani I, Di Nicola M, Gianni AM, Pilotti S, Dunbar R, Cerundolo V, Parmiani G. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions. J Exp Med 1999; 190: 651-67.
8. Pittet MJ, Valmori D, Dunbar PR, Speiser DE, Lienard D, Lejeune F, Fleischhauer K, Cerundolo V, Cerottini JC, Romero P. High frequencies of naive Melan-A/MART-1-specific CD8 (+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J Exp Med 1999; 190: 705-15.
9. Valmori D, Pittet MJ, Rimoldi D, Lienard D, Dunbar R, Cerundolo V, Lejeune F, Cerottini JC, Romero P. An antigen-targeted approach to adoptive transfer therapy of cancer. Cancer Res 1999; 59: 2167-73.
10. Coulie PG, Karanikas V, Colau D, Lurquin C, Landry C, Marchand M, Dorval T, Brichard V, Boon T. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA 2001; 98: 10290-5.
11. Appay V, Nixon DF, Donahoe SM, Gillespie GM, Dong T, King A, Ogg GS, Spiegel HM, Conlon C, Spina CA, Havlir DV, Richman DD, Waters A, Easterbrook P, McMichael AJ, Rowland-Jones SL. HIV-specific CD8 (+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 2000; 192: 63-75.
12. Reignat S, Webster GJ, Brown D, Ogg GS, King A, Seneviratne SL, Dusheiko G, Williams R, Maini MK, Bertoletti A. Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med 2002; 195: 1089-101.
13. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MM. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999; 5: 677-85.
14. Rubio-Godoy V, Dutoit V, Rimoldi D, Lienard D, Lejeune F, Speiser D, Guillaume P, Cerottini JC, Romero P, Valmori D. Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life. Proc Natl Acad Sci USA 2001; 98: 10302-7.
15. Kuroda MJ, Schmitz JE, Charini WA, Nickerson CE, Lord CI, Forman MA, Letvin NL. Comparative analysis of cytotoxic T lymphocytes in lymph nodes and peripheral blood of simian immunodeficiency virus-infected rhesus monkeys. J Virol 1999; 73: 1573-9.
16. Wang CY, Looney DJ, Li ML, Walfield AM, Ye J, Hosein B, Tam JP, Wong-Staal F. Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen. Science 1991; 254: 285-8.
17. Chai SK, Clavijo P, Tam JP, Zavala F. Immunogenic properties of multiple antigen peptide systems containing defined T and B epitopes. J. Immunol 1992; 149: 1573-9.
18. Huang W, Nardelli B, Tam JP. Lipophilic multiple antigen peptide system for peptide immunogen and synthetic vaccine. Mol Immunol 1994; 31: 1191-9.
19. Nardelli B, Tam JP. Cellular immune responses induced by in vivo priming with a lipid-conjugated multimeric antigen peptide. Immunology 1993; 79: 355-61.
20. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-12.
21. Reinhardt RL, Khoruts A, Merica R, Zell T, Jenkins MK. Visualizing the generation of memory CD4 T cells in the whole body. Nature 2001; 410: 101-5.
22. Nakayama E, Uenaka A. Effect of in vivo administration of Lyt antibodies. Lyt phenotype of T cells in lymphoid tissues and blocking of tumor rejection. J Exp Med 1985; 161: 345-55.